Bioworld Consulting Laboratories, LLC (BCL) designs, develops, manufactures and markets monoclonal antibodies, antigens and new methods for detection and identification of viral infectious agents.

BCL has a complete and innovative range of technologies, enabling the company to take advantage of growth in the most dynamic market segments:

  • Monoclonal antibodies -- company developed a rapid immunization and hybridoma development method which allows delivery of custom made monoclonal antibodies in 6 to10 weeks.
  • Rapid Immunoassays -- detection and measurement of infectious agents and pathology markers based on an antigen/antibody reaction using newly developed rapid and sensitive assays. Generally these assays are done in 10-20 minutes compared to traditional assays which may take several hours to complete. In most cases the sensitivity is two to eight fold better than the corresponding traditional method.
  • Molecular biology -- a new technology is under development, which allows detection of a single copy of DNA or RNA in situ in less than one hour. Estimated release of the kit using the new method for detection of EBV, HHV-6 and HHV-7 is December 2009.